Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

Clinical trial NCT04488003 · TERMINATED

Trial details

NCT number: NCT04488003
Sponsor: BioMed Valley Discoveries, Inc
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Advanced Solid Tumor BRAF Gene Mutation BRAF Gene Alteration MEK Mutation MEK Alteration MAP2K1 Gene Mutation MAP2K1 Gene Alteration MAP2K2 Gene Mutation MAP2K2 Gene Alteration

Start date: 2021-01-07
Primary completion: 2023-02-15
Enrollment: 104

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.